Autoinhibitory structure of preligand association state implicates a new strategy to attain effective DR5 receptor
Gang Du1, Linlin Zhao1,2, Yumei Zheng1,3
1Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Abstract:
Members of the tumor necrosis factor receptor superfamily (TNFRSF) are important therapeutic targets that can be activated to induce death of cancer cells or stimulate proliferation of immune cells. Although it has long been implicated that these receptors assemble preligand associated states that are required for dominant interference in human disease, such states have so far eluded structural characterization. Here, we find that the ectodomain of death receptor 5 (DR5-ECD), a representative member of TNFRSF, can specifically self-associate when anchored to lipid bilayer, and we report this self-association structure determined by nuclear magnetic resonance (NMR). Unexpectedly, two non-overlapping interaction interfaces are identified that could propagate to higher-order clusters. Structure-guided mutagenesis indicates that the observed preligand association structure is represented on DR5-expressing cells. The DR5 preligand association serves an autoinhibitory role as single-domain antibodies (sdAbs) that partially dissociate the preligand cluster can sensitize the receptor to its ligand TRAIL and even induce substantial receptor signaling in the absence of TRAIL. Unlike most agonistic antibodies that require multivalent binding to aggregate receptors for activation, these agonistic sdAbs are monovalent and act specifically on an oligomeric, autoinhibitory configuration of the receptor. Our data indicate that receptors such as DR5 can form structurally defined preclusters incompatible with signaling and that true agonists should disrupt the preligand cluster while converting it to signaling-productive cluster. This mechanism enhances our understanding of a long-standing question in TNFRSF signaling and suggests a new opportunity for developing agonistic molecules by targeting receptor preligand clustering.
Insights
Death receptor 5 (DR5) forms autoinhibitory preclusters on cell surfaces. Disrupting these preclusters with single-domain antibodies (sdAbs) activates DR5 signaling, offering new therapeutic strategies for cancer and immune disorders.
Area of Science:
- Structural biology
- Immunology
- Cancer biology
Background:
- Members of the tumor necrosis factor receptor superfamily (TNFRSF) are crucial therapeutic targets for cancer and immune cell modulation.
- The preligand association states of TNFRSF, essential for disease interference, have lacked structural characterization.
Purpose of the Study:
- To structurally characterize the self-association of the death receptor 5 ectodomain (DR5-ECD).
- To elucidate the role of DR5 preligand association in receptor signaling and its potential as a therapeutic target.
Main Methods:
- Nuclear magnetic resonance (NMR) spectroscopy to determine the self-association structure of DR5-ECD.
- Structure-guided mutagenesis to validate the preligand association structure on cells.
- Functional assays using single-domain antibodies (sdAbs) to assess receptor activation.
Main Results:
- DR5-ECD forms specific self-associated structures on lipid bilayers with two distinct interaction interfaces.
- This preligand association structure is present on DR5-expressing cells and functions in an autoinhibitory manner.
- Monovalent agonistic sdAbs that partially dissociate DR5 preclusters sensitize the receptor to TRAIL and induce signaling independently of TRAIL.
Conclusions:
- DR5 receptors form structurally defined, signaling-incompetent preclusters.
- Agonistic molecules can activate TNFRSF by disrupting preclusters and promoting signaling-productive clusters.
- Targeting receptor preligand clustering presents a novel strategy for developing TNFRSF-based therapeutics.
Related Concept Videos
The Two-State Receptor Model
The binding affinity of a drug determines its interaction with...
GPCR Desensitization
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Activation and Inactivation of G Proteins
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Drug-Receptor Interactions
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....


